I believe the following stocks could be on the upside move, today, Wednesday April 18th, 2012, which could make for a nice short term gain for those who prefer short term swing trading.
Achillion (ACHN) Achillion will be releasing results of its Phase IIa clinical trials of ACH-1625 on April 18-22, at the International Liver Conference being hosted in Barcelona. ACH-1625 is an Hepatitis C virus (HCV) protease inhibitor.
Price moving factor: Achillion's release of this data should also have a price effect on stocks like Bristol-Myers Squibb (BMY), which shelled out $2 billion in cash to scoop up Inhibitex, maker of the hepatitis C treatment INX-189 in a transaction that carried a whopping 163% premium, and Gilead Sciences (GILD), which struck a deal to buy Pharmasset in November 2011 for $11 billion. Gilead paid $137 per share for the company, which seized wide attention for its work on new hepatitis C treatments that may do away with the need for interferon and create a new standard of care for the disease.
Gilead has taken on Pharmasset's PSI-7977, which has two late-stage studies involving genotype 2 and 3 patients. One study is comparing the oral therapy combined with ribavirin against the standard-of-care, pegylated interferon/ribavirin in treatment-naive patients. The second study is comparing PSI-7977 to a placebo in interferon-intolerant or ineligible patients. A third Phase III launches in the second half of 2012.
There is a large reward for the company that successfully gets the most effective Hep-C treatment to market first -- a multi-billion dollar market.
GTX (GTXI) engages in the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.
Price moving factor: Run-up to FDA decision on trial resumption of its drug Capesaris. Capesaris is a prostate cancer drug that chemically castrates prostate cancer patients. GTX discovered larger dosages of the drug caused some side effects, including the increased risk of blood clots.
The company's plans to administer lower doses of Capesaris throughout the remainder of the trial to address the FDA's concerns before the trials can officially continue. The FDA will decide whether GTX has demonstrated its drug is safe enough to allow the phase II trial to continue in 30 days.
I have heard that some bigger money players are accumulating this stock for the run-up catalyst event.
Xenoport (XNPT) focuses on developing and commercializing internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs.
Price moving factor: PDUFA 6/9/12 for sNDA of Horizant for post-herpetic neuralgia (PHN).
Horizant utilizes naturally-occurring, high-capacity nutrient transporters in the gastrointestinal tract to generate active, efficient absorption into the body. Once absorbed, gabapentin enacarbil is rapidly converted into gabapentin, which binds to specific proteins that regulate neuronal activity, and is thereby thought to inhibit unnecessary excitatory neurological activity. Neuropathic pain is pain that results from damage to nerves. The damage may result from a variety of causes, including injury or illnesses such as diabetes, HIV and shingles.
In other words, Horizant is used to treat pain.
Horizon Pharma (HZNP) develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases.
Price moving factor: PDUFA 7/26/12 of LODOTRA, a proprietary modified delayed-release formulation of prednisone, for the treatment of rheumatoid arthritis in adults.
Insiders have been buying up a lot of its company's shares. I recently sold Horizon as I reached my short term target price. I am considering trading it again. I like Horizon quite a bit and believe it has longer term potential if LODOTRA gains approval.
Protalix BioTherapeutics (PLX) focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States.
Price moving factor: PDUFA 5/1/12 of Taligluerase for Gaucher disease.
Taligluerase is a plant cell-expressed recombinant glucocerebrosidase enzyme for the potential treatment of Gaucher disease. Protalix is partnered with Pfizer (PFE) for the exclusive worldwide commercialization of taliglucerase alfa in all territories, except in Israel, where Protalix has retained exclusive rights. Protalix completed the pivotal Phase 3 trial, and patients from the pivotal study were enrolled into an extension study, with some patients being treated for greater than three years. Taliglucerase alfa has been granted orphan drug designation by both the FDA and the European Medicines Agency.
iBio (IBIO) engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary technology, the iBioLaunch platform. Its product portfolio consists of seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus.
Price moving factor: Protalix's PDUFA 5/1/12 of Taligluerase for Gaucher disease.
iBio is the only other known company with a listing on the American stock market with similar technology, and in my opinion, has more long term upside appreciation potential than Protalix. iBio's technology platform is named iBioLaunch.
I recently wrote a feature article where I get in-depth on why I believe iBio is a very strong speculative long term investment.
Honorable price mover mentions:
pSivida (PSDV): Looks like serious accumulation occurring over the last 2 weeks, possible break-out coming. I have a feature article coming out on pSivida today.
Antares Pharma (AIS) : Feature article coming out today with 10 reasons why I believe Antares will be bought out soon.
Disclosure: I am long AIS.